blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3965828

EP3965828 - EXOSOME COMPRISING STABILIZED RNA THERAPEUTICS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  27.04.2024
Database last updated on 28.06.2024
FormerThe patent has been granted
Status updated on  19.05.2023
FormerGrant of patent is intended
Status updated on  07.12.2022
FormerRequest for examination was made
Status updated on  11.02.2022
FormerThe international publication has been made
Status updated on  13.11.2020
Formerunknown
Status updated on  19.05.2020
Most recent event   Tooltip24.05.2024Lapse of the patent in a contracting state
New state(s): IT, SI		published on 26.06.2024  [2024/26]
Applicant(s)For all designated states
Evox Therapeutics Ltd
Oxford Science Park
Medawar Centre
2nd Floor East Building
Robert Robinson Avenue
Oxford OX4 4HG / GB
[2023/25]
Former [2022/11]For all designated states
Evox Therapeutics Limited
Oxford Science Park
Medawar Centre
2nd Floor East Building
Robert Robinson Avenue
Oxford, Oxfordshire OX4 4HG / GB
Inventor(s)01 / CASTILLA LLORENTE, Virginia
Oxford Science Park Medawar Centre 2nd Floor East
Building Robert Robinson Avenue
Oxford Oxfordshire OX4 4HG / GB
02 / LIANG, Xiuming
Terapivagen 14C, LGH1701 Huddinge
14156 Stockholm / SE
03 / ZICKLER, Antje
Sveavägen 164L, Apt. L14
11346 Stockholm / SE
04 / DE LUCA, Mariacristina
5 Grove Court, Church Way
Oxford Oxfordshire OX4 4EP / GB
05 / ERRICHELLI, Lorenzo
6 Olney Court, Marlborough Road
Oxford Oxfordshire OX1 4LZ / GB
06 / SMITH, Christopher
5 Grove Court, Church Way
Oxford Oxfordshire OX4 4EP / GB
07 / TSALIC, Ran
11 Wellesborne Close
Abingdon Oxfordshire OX14 3UR / GB
 [2022/11]
Representative(s)Greaves Brewster LLP
Copa House
Station Road
Cheddar, Somerset BS27 3AH / GB
[N/P]
Former [2022/11]Cooley (UK) LLP
22 Bishopsgate
London EC2N 4BQ / GB
Application number, filing date20724828.707.05.2020
[2022/11]
WO2020EP62791
Priority number, dateGB2019000648208.05.2019         Original published format: GB 201906482
[2022/11]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020225392
Date:12.11.2020
Language:EN
[2020/46]
Type: A1 Application with search report 
No.:EP3965828
Date:16.03.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 12.11.2020 takes the place of the publication of the European patent application.
[2022/11]
Type: B1 Patent specification 
No.:EP3965828
Date:21.06.2023
Language:EN
[2023/25]
Search report(s)International search report - published on:EP12.11.2020
ClassificationIPC:A61K47/69, A61K47/64, C12N15/11, C12N15/88, C07K14/705, A61P43/00, C07K14/47
[2022/49]
CPC:
A61K47/6901 (EP,US); A61K47/64 (EP,US); A61K9/5068 (EP,US);
A61P43/00 (EP); C07K14/4702 (EP,US); C07K14/705 (EP);
C07K14/70596 (US); C12N15/111 (EP,US); C12N15/88 (EP,US);
C12N9/22 (US); C07K2319/33 (EP,US); C07K2319/50 (EP,US);
C07K2319/85 (EP,US); C12N2310/14 (EP); C12N2320/32 (EP,US);
C12N2800/80 (US) (-)
Former IPC [2022/11]A61K47/69, A61K47/64, C12N15/11, C12N15/88, C07K14/705
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/11]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:EXOSOM MIT STABILISIERTEN RNA-THERAPEUTIKA[2022/11]
English:EXOSOME COMPRISING STABILIZED RNA THERAPEUTICS[2022/11]
French:EXOSOMES COMPRENANT DES AGENTS THÉRAPEUTIQUES À BASE D'ARN STABILISÉS[2022/11]
Entry into regional phase15.11.2021National basic fee paid 
15.11.2021Designation fee(s) paid 
15.11.2021Examination fee paid 
Examination procedure05.03.2021Request for preliminary examination filed
International Preliminary Examining Authority: EP
15.11.2021Examination requested  [2022/11]
15.11.2021Date on which the examining division has become responsible
25.05.2022Amendment by applicant (claims and/or description)
08.12.2022Communication of intention to grant the patent
30.03.2023Fee for grant paid
30.03.2023Fee for publishing/printing paid
30.03.2023Receipt of the translation of the claim(s)
Opposition(s)22.03.2024No opposition filed within time limit [2024/22]
Fees paidRenewal fee
20.03.2022Renewal fee patent year 03
15.05.2023Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT21.06.2023
CZ21.06.2023
DK21.06.2023
EE21.06.2023
ES21.06.2023
FI21.06.2023
HR21.06.2023
IT21.06.2023
LT21.06.2023
LV21.06.2023
NL21.06.2023
PL21.06.2023
RO21.06.2023
RS21.06.2023
SE21.06.2023
SI21.06.2023
SK21.06.2023
SM21.06.2023
NO21.09.2023
GR22.09.2023
IS21.10.2023
PT23.10.2023
[2024/26]
Former [2024/22]AT21.06.2023
CZ21.06.2023
DK21.06.2023
EE21.06.2023
ES21.06.2023
FI21.06.2023
HR21.06.2023
LT21.06.2023
LV21.06.2023
NL21.06.2023
PL21.06.2023
RO21.06.2023
RS21.06.2023
SE21.06.2023
SK21.06.2023
SM21.06.2023
NO21.09.2023
GR22.09.2023
IS21.10.2023
PT23.10.2023
Former [2024/10]AT21.06.2023
CZ21.06.2023
EE21.06.2023
ES21.06.2023
FI21.06.2023
HR21.06.2023
LT21.06.2023
LV21.06.2023
NL21.06.2023
PL21.06.2023
RO21.06.2023
RS21.06.2023
SE21.06.2023
SK21.06.2023
SM21.06.2023
NO21.09.2023
GR22.09.2023
IS21.10.2023
PT23.10.2023
Former [2024/09]AT21.06.2023
CZ21.06.2023
ES21.06.2023
FI21.06.2023
HR21.06.2023
LT21.06.2023
LV21.06.2023
NL21.06.2023
RS21.06.2023
SE21.06.2023
SK21.06.2023
SM21.06.2023
NO21.09.2023
GR22.09.2023
IS21.10.2023
Former [2024/08]FI21.06.2023
HR21.06.2023
LT21.06.2023
LV21.06.2023
NL21.06.2023
RS21.06.2023
SE21.06.2023
SK21.06.2023
SM21.06.2023
NO21.09.2023
GR22.09.2023
Former [2024/03]FI21.06.2023
HR21.06.2023
LT21.06.2023
LV21.06.2023
NL21.06.2023
RS21.06.2023
SE21.06.2023
NO21.09.2023
GR22.09.2023
Former [2024/01]HR21.06.2023
LT21.06.2023
LV21.06.2023
NL21.06.2023
RS21.06.2023
SE21.06.2023
NO21.09.2023
GR22.09.2023
Former [2023/52]HR21.06.2023
NL21.06.2023
RS21.06.2023
SE21.06.2023
NO21.09.2023
GR22.09.2023
Former [2023/51]HR21.06.2023
RS21.06.2023
SE21.06.2023
NO21.09.2023
GR22.09.2023
Former [2023/50]SE21.06.2023
NO21.09.2023
GR22.09.2023
Former [2023/48]SE21.06.2023
NO21.09.2023
Cited inInternational search[IDP]WO2019092145  (EVOX THERAPEUTICS LTD [GB]) [IDP] 1-29* the whole document *;
 [X]  - Lysangela R. Alves ET AL, "Extracellular vesicle-mediated RNA release in Histoplasma 2 capsulatum", bioRxiv, doi:10.1101/570291, (20190307), URL: https://www.biorxiv.org/content/10.1101/570291v1.full.pdf, (20200727), XP055718329 [X] 1,7,14-17 * sentences 98,155-157 * * tables 1,2 *

DOI:   http://dx.doi.org/10.1101/570291
 [X]  - MICHELLE E. HUNG ET AL, "A platform for actively loading cargo RNA to elucidate limiting steps in EV-mediated delivery", JOURNAL OF EXTRACELLULAR VESICLES, (20160101), vol. 5, no. 1, doi:10.3402/jev.v5.31027, page 31027, XP055711976 [X] 22,23,25,26 * abstract * * page 5, column 1, paragraph 2 * * figure 1 *

DOI:   http://dx.doi.org/10.3402/jev.v5.31027
 [X]  - DHRUVITKUMAR S. SUTARIA ET AL, "Low active loading of cargo into engineered extracellular vesicles results in inefficient miRNA mimic delivery", JOURNAL OF EXTRACELLULAR VESICLES, (20170614), vol. 6, no. 1, doi:10.1080/20013078.2017.1333882, page 1333882, XP055611131 [X] 22,23,25,26 * abstract * * figure 1 *

DOI:   http://dx.doi.org/10.1080/20013078.2017.1333882
 [X]  - DHRUVITKUMAR S. SUTARIA ET AL, "Achieving the Promise of Therapeutic Extracellular Vesicles: The Devil is in Details of Therapeutic Loading", PHARMACEUTICAL RESEARCH, US, (20170317), vol. 34, no. 5, doi:10.1007/s11095-017-2123-5, ISSN 0724-8741, pages 1053 - 1066, XP055543423 [X] 22,23,25,26 * page 9, section "Targeted and Modular EV Loading Approach" *

DOI:   http://dx.doi.org/10.1007/s11095-017-2123-5
by applicantWO2010119256
    - HUNGLEONARD, Journal of Extracellular Vesicles, (20160000), vol. 5, page 31027
    - TUTUCCI et al., "An improved MS2 system for accurate reporting of the mRNA life cycle", Nat Methods, (20180100), vol. 15, no. 1, pages 81 - 89
    - DEVEREUX et al., Nucleic Acids Research, (19840000), vol. 12, pages 387 - 395
    - ALTSCHUL S. F., J Mol Evol, (19930000), vol. 36, pages 290 - 300
    - ALTSCHUL, S. F et al., J Mol Biol, (19900000), vol. 215, pages 403 - 10
 WO2017GB51479
 WO2018EP80681
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.